|1.||Chipkin, Richard: 1 article (08/2014)|
|2.||Kim, Suck Won: 1 article (08/2014)|
|3.||Fong, Timothy: 1 article (08/2014)|
|4.||Black, Donald W: 1 article (08/2014)|
|5.||Odlaug, Brian L: 1 article (08/2014)|
|6.||Davtian, Margarit: 1 article (08/2014)|
|7.||Grant, Jon E: 1 article (08/2014)|
|8.||Gilbert, Donald L: 1 article (01/2014)|
|9.||Singer, Harvey S: 1 article (01/2014)|
|10.||Kurlan, Roger: 1 article (01/2014)|
|1.||Schizophrenia (Dementia Praecox)
10/01/1995 - "In the present open study the effects of the D1-dopamine antagonist SCH 39166 on positive and negative symptoms of schizophrenia (DSM-IIIR) were investigated. "
10/01/1995 - "SCH 39166 is the first selective D1-dopamine receptor antagonist developed for clinical trials in schizophrenia. "
12/01/1991 - "SCH 39166 [(-)-trans-6,7,7a,8,9, 13b-hexahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo-[d]naphtho[2, 1b]azepine] has recently been described as a selective D1 antagonist and has entered clinical trials for the treatment of schizophrenia. "
03/01/1998 - "A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia."
10/01/1995 - "Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia."
|2.||Weight Loss (Weight Reduction)
07/01/2007 - "Ecopipam was effective for achieving and maintaining weight loss in obese subjects, including type 2 diabetic subjects; however, the adverse effects on mood observed in the Phase 3 studies exclude its projected use in weight management."
07/01/2007 - "More subjects administered ecopipam vs. placebo achieved a 5% to 10% or >10% weight loss in two non-diabetic phase 3 trials. "
07/01/2007 - "In the Phase 3 studies, ecopipam 100 mg produced a 3.1% to 4.3% greater weight loss than placebo at 52 weeks. "
07/01/2007 - "In the Phase 2 study, 26% of subjects administered ecopipam 100 mg vs. 6% of placebo subjects achieved>or=5% weight loss after 12 weeks (p<0.01). "
07/01/2007 - "Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects."
|3.||Gambling (Pathological Gambling)
08/01/2014 - "Ecopipam may offer promise for treating gambling disorder because of its antagonism of dopamine-1 receptors. "
08/01/2014 - "Twenty-eight individuals with gambling disorder were enrolled and received ≥1 dose of oral ecopipam in an 8-week trial (1 week placebo lead-in, 6 weeks of medication (50 to 100 mg/d as needed), and 1 week follow-up. "
08/01/2014 - "A single-blind study of 'as-needed' ecopipam for gambling disorder."
01/01/1992 - "The ability of these two doses of SCH 39166 to induce catalepsy in the bar test was also evaluated. "
12/01/1988 - "administration of SCH39166 using the inclined screen test, the drug did not cause catalepsy at doses up to 10 times its minimal effective dose in the rat conditioned avoidance response test. "
07/01/1995 - "Intrastriatal injections of SCH 39166 (1.5 and 3.6 micrograms/ 0.5 microliters) also evoked a dose-dependent, but short-lasting catalepsy. "
06/01/2000 - "In observational studies, SKF 83959 and SKF 77434 produced less severe disruptions in motor behavior than did SCH 39166 and, for SKF 83959, showed a greater separation between the dose required to antagonize the behavioral effects of cocaine and the dose that induced catalepsy (>/=33-fold). "
07/01/1995 - "Since highly specific antagonists of D1 (SCH 39166) and D2 (raclopride) dopamine receptors have recently become available, we decided to investigate the role of striatal populations of these receptors in catalepsy - an animal model of neuroleptic-induced parkinsonism in humans. "
|5.||Cocaine-Related Disorders (Cocaine Addiction)
06/01/2012 - "A specific example of an apparently promising pharmacotherapeutic for cocaine addiction (the D1 dopamine receptor antagonist ecopipam) that failed clinically will be examined to determine if this truly represents a challenge to the predictive validity of current models of cocaine addiction. "
06/01/2001 - "Although the performance effects verify that these doses of ecopipam were behaviorally active, the absence of an attenuation of cocaine's effects of craving for cocaine in this chronic dosing paradigm suggests this compound is unlikely to be an effective pharmacotherapy for cocaine abuse."
12/01/1999 - "This study examined the role of dopamine D1-like receptors in the behavioral and mood effects of cocaine by evaluating the effects of the selective D1/D5 antagonist ecopipam (SCH 39166) on subjective responses to intravenous cocaine in 11 subjects with cocaine dependence as defined by DSM-IV. Subjects were pretreated in a randomized double-blind fashion with either placebo or 10 mg, 25 mg, or 100 mg of ecopipam orally on 4 separate occasions. "
|1.||Antipsychotic Agents (Antipsychotics)
|2.||Cocaine (Cocaine HCl)
|5.||Dopamine D1 Receptors (Dopamine D1 Receptor)
|6.||Dopamine Receptors (Dopamine Receptor)
|2.||Drug Therapy (Chemotherapy)